Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1964 2
1965 1
1966 1
1967 2
1968 1
1969 2
1970 2
1971 1
1972 3
1973 1
1974 4
1976 7
1977 1
1978 2
1979 2
1980 3
1981 5
1982 8
1983 7
1984 6
1985 6
1986 6
1987 11
1988 10
1989 6
1990 11
1991 15
1992 10
1993 8
1994 13
1995 3
1996 13
1997 8
1998 10
1999 17
2000 14
2001 20
2002 5
2003 8
2004 7
2005 13
2006 19
2007 9
2008 10
2009 19
2010 22
2011 19
2012 22
2013 21
2014 25
2015 18
2016 21
2017 24
2018 17
2019 19
2020 15
2021 18
2022 12
Text availability
Article attribute
Article type
Publication date

Search Results

549 results
Results by year
Filters applied: . Clear all
Page 1
Chronic venous disease.
Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Bergan JJ, et al. Among authors: smith pd. N Engl J Med. 2006 Aug 3;355(5):488-98. doi: 10.1056/NEJMra055289. N Engl J Med. 2006. PMID: 16885552 Review. No abstract available.
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.
Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. Verma V, et al. Among authors: smith pd. Nat Immunol. 2021 Jan;22(1):53-66. doi: 10.1038/s41590-020-00818-9. Epub 2020 Nov 23. Nat Immunol. 2021. PMID: 33230330
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
Colclough N, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varnäs K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, Zhang L, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, Malmquist J, Revunov E, Vazquez-Romero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV, Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE. Colclough N, et al. Among authors: smith pd. Clin Cancer Res. 2021 Jan 1;27(1):189-201. doi: 10.1158/1078-0432.CCR-19-1871. Epub 2020 Oct 7. Clin Cancer Res. 2021. PMID: 33028591
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, Unni AM, Homer R, Lockwood WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross DAE, Politi K. Starrett JH, et al. Among authors: smith pd. Cancer Res. 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19. Cancer Res. 2020. PMID: 32193290 Free PMC article.
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
Eser PÖ, Paranal RM, Son J, Ivanova E, Kuang Y, Haikala HM, To C, Okoro JJ, Dholakia KH, Choi J, Eum Y, Ogino A, Missios P, Ercan D, Xu M, Poitras MJ, Wang S, Ngo K, Dills M, Yanagita M, Lopez T, Lin M, Tsai J, Floch N, Chambers ES, Heng J, Anjum R, Santucci AD, Michael K, Schuller AG, Cross D, Smith PD, Oxnard GR, Barbie DA, Sholl LM, Bahcall M, Palakurthi S, Gokhale PC, Paweletz CP, Daley GQ, Jänne PA. Eser PÖ, et al. Among authors: smith pd. Sci Transl Med. 2021 Sep;13(609):eabb3738. doi: 10.1126/scitranslmed.abb3738. Epub 2021 Sep 1. Sci Transl Med. 2021. PMID: 34516823 Free PMC article.
Dental Care Access.
Desai BK, Boyd CJ, Smith PD. Desai BK, et al. Among authors: smith pd. J Am Dent Assoc. 2021 Jun;152(6):421-422. doi: 10.1016/j.adaj.2021.04.005. J Am Dent Assoc. 2021. PMID: 34044967 No abstract available.
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, Cooper ZA, Streicher K. Tu E, et al. Among authors: smith pd. JCI Insight. 2022 Feb 8;7(3):e142843. doi: 10.1172/jci.insight.142843. JCI Insight. 2022. PMID: 35132961 Free PMC article.
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.
Floc'h N, Lim S, Bickerton S, Ahmed A, Orme J, Urosevic J, Martin MJ, Cross DAE, Cho BC, Smith PD. Floc'h N, et al. Among authors: smith pd. Mol Cancer Ther. 2020 Nov;19(11):2298-2307. doi: 10.1158/1535-7163.MCT-20-0103. Epub 2020 Sep 17. Mol Cancer Ther. 2020. PMID: 32943544
549 results